Abstract
ABSTRACT Introduction The incidence of lung cancer increases with age. Given the increasing comorbid conditions and progressive reduction of organ function, it is presumed that the elderly are not more likely to tolerate to the cytotoxic chemotherapy. However, prospective data on adjuvant chemotherapy in elderly patients are not available. Methods Patients with completely resected stage Ib, II or IIIa NSCLC were enrolled for this analysis. Either four cycles of paclitaxel–carboplatin or vinorelbine–cisplatin was used as an adjuvant chemotherapeutic regimen. The primary objective was to assess the health-related quality of life (HRQOL) of elderly patients (age ≥65), during and after post-operative chemotherapy. The secondary objective included comparison of HRQOL by age (≥65 versus Results Between October 2008 and October 2011, a total of 113 patients were enrolled; aged Conclusion Post-operative chemotherapy did not substantially reduced HRQOL in elderly NSCLC patients, and HRQOL during and after adjuvant chemotherapy did not differ by age (
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
